Business Context and Reporting Period
Pavmed Inc. filed this Form 8-K on January 26, 2017, to report the entry into a Material Definitive Agreement and the unregistered sale of equity securities. The company, a Delaware corporation, executed a Securities Purchase Agreement to raise capital through a private placement of Units.
Key Financial Metrics
- Gross Proceeds: $1,508,004 raised from the sale of 251,334 Units.
- Transaction Costs: $105,556.28 in aggregate commissions paid.
- Net Proceeds: $1,238,343.72.
- Offering Price: $6.00 per Unit.
- Offering Capacity: Up to $3,000,000 aggregate, with potential for increase upon consent.
- Dividend Rate: 8% per annum cumulative on Series A Preferred Stock (compounded quarterly).
Material Changes and Transaction Details
The company closed two tranches of the offering on January 26, 2017 (211,334 Units) and January 31, 2017 (40,000 Units). Each Unit consists of one share of Series A Convertible Preferred Stock and one Series A Warrant. The Series A Preferred Stock is convertible into Common Stock at an initial price of $6.00. The Series A Warrants are exercisable for Common Stock at $8.00 and are exchangeable for four Series X Warrants (exercisable at $6.00). The company also entered into a Registration Rights Agreement requiring a registration statement to be filed within 60 days and declared effective within 150 days.
Outlook, Risks, and Contingencies
- Stockholder Approval: Exercise of Series A Warrants and conversion of Preferred Stock is contingent upon obtaining stockholder approval under Nasdaq Rule 5635(d) due to potential issuance of 20% or more of outstanding shares below market price.
- Dividend Payment: Dividends accrue regardless of earnings. Through April 1, 2021, dividends are payable in-kind (additional shares). Thereafter, the company may pay in cash, Preferred Stock, or Common Stock.
- Liquidation Preference: Series A holders have priority over Common Stockholders in liquidation, entitled to the greater of the Stated Value plus accrued dividends or the conversion value.
- Redemption Risk: The company may redeem Series X Warrants at $0.01 per warrant after April 30, 2019, if the Common Stock price exceeds $18.00 for a specified period.
Investor Verification Checklist
- Verify the status of the required stockholder approval under Nasdaq Rule 5635(d) to determine when Warrants and Preferred Stock can be converted/exercised.
- Confirm the timeline for the filing and effectiveness of the Registration Statement for resale of securities.
- Monitor the company's cash position to assess its ability to fund operations given the 8% cumulative dividend obligation on the Preferred Stock.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for specific anti-dilution adjustment mechanics.
- Check for any additional closings to determine if the full $3,000,000 offering capacity was utilized.